Pegozafermin lowers high triglycerides, non-HDL and ApoB vs. placebo in small trial
June 09 ,2023
Overview:Pegozafermin, a fibroblast growth factor 21 analog, reduced atherogenic particles in patients with severe hypertriglyceridemia and improved liver fat and insulin resistance compared with placebo, a speaker reported.Michael Miller, MD, FACC, FAHA, chief of medicine at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia and vice chair of medicine at the University of Pennsylvania School of Medicine, presented the results of the phase 2, randomized, double-blind ENTRIGUE trial at the National Lipid Association Scientific Sessions.“Fibroblast growth factor 21 (FGF21) is an more
CAC screening, follow-up care lacking among Black patients in small study
June 09 ,2023
Overview:Black patients who undergo coronary artery calcium scoring received less post-screening care and had more adverse CV events compared with white patients at a single center, a speaker reported.The results of the retrospective IMPACT study were presented at the National Lipid Association Scientific Sessions.“Atherosclerotic coronary artery disease is the leading cause of death among every racial and ethnic group. Worldwide prevalence is about 5% to 8%, accounting for about 7 million deaths. In the U.S. about 20.1 million adults, or 7.2%, have CAD, with someone having a heart attack every more
Xenotransplantation: Are we ready for clinical trials in humans?
June 08 ,2023
Overview:For this month’s Infectious Disease News cover story, we touched base with experts in transplant medicine and transplant infectious diseases to discuss recent challenges brought on by the pandemic and the country’s organ shortage crisis.One potential solution to the organ shortage is xenotransplantation — transplanting organs from other species into humans.Last year, a team at the University of Maryland Medical Center performed the first transplant of a genetically-modified pig heart into a 57-year-old man with terminal heart disease. The surgery was a success and hailed as more
Addressing disparities in ASCVD within the US South Asian population
June 08 ,2023
Overview:The South Asian population in the U.S. is one of the fastest-growing minority ethnic groups, and these individuals are a particularly higher-risk population.The U.S. South Asian population has rates of atherosclerotic CVD approximately 2.5 times greater than other racial and ethnic groups, particularly when compared with non-Hispanic white individuals. In addition to an increased prevalence of ASCVD, the development of atherosclerosis and subsequent clinical consequences (specifically, MI) often occurs approximately 5 years earlier in South Asian patients compared with their non-Hispanic more
AI for preprocedural TAVR modeling gains FDA clearance
June 07 ,2023
Overview:Dasi Simulations announced it received FDA clearance for its artificial intelligence model for preprocedure transcatheter aortic valve replacement modeling.The AI (Precision TAVI) is the company’s first product to be cleared by the FDA, according to a company press release.“Dasi Simulations empowers every heart team with critical insights guaranteeing the identification of the best possible care for individual patients, customized to their unique circumstances and anatomy,” Lakshmi (Prasad) Dasi, PhD, FACC, FAIMBE, cofounder and chief technology officer of Dasi Simulations, more
Wearable devices ‘substantially underused’ among people with heart disease
June 07 ,2023
Overview:Fewer than one in four people with or at risk for heart disease use wearable devices, with only half of those reporting consistent daily use, researchers reported.In a nationally representative study of contemporary patterns of wearable device use among U.S. adults, researchers estimated that 72 million U.S. adults, or about one-third of the U.S. adult population, used wearable devices, and the use was significantly lower among those with CVD, with only 18% reporting wearable use. Additionally, one-quarter of adults with CVD who used wearable devices reported not using their device in the more
ROSE2: Obicetrapib/ezetimibe combination further lowers LDL in statin-treated patients
June 07 ,2023
Overview:In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial.As Healio previously reported, obicetrapib (NewAmsterdam Pharma), an investigational cholesteryl ester transfer protein (CETP) inhibitor, decreased LDL, non-HDL, lipoprotein(a) and apolipoprotein B and increased HDL at 8 weeks in the ROSE trial of patients with dyslipidemia on statin therapy.For the ROSE2 trial, presented at the National Lipid Association Scientific Sessions and published in the Journal of Clinical Lipidology, the more
Medicaid beneficiaries with diabetes, HF often do not receive best care after discharge
June 07 ,2023
Overview:Among Medicaid beneficiaries with diabetes and heart failure in Alabama, many did not have a follow-up visit within 14 days of hospitalization in accordance with guidelines, researchers reported.There were racial and ethnic disparities in who had a visit, whether it was within 14 days after hospitalization and whether it was to a primary care physician, according to the researchers.The study “likely demonstrates system-related factors, such as problems in the transitions of care between hospitals and clinics, and also structural racism that exists in the health care system,” Yulia more
Societies call for lipid panels to be CMS main quality measure of LDL control
June 07 ,2023
Overview:Lipid panels, not statin prescription alone, should be reconsidered as a quality and performance measure of LDL control, according to a joint perspective from the National Lipid Association and American Society for Preventive Cardiology.During a presentation at the National Lipid Association (NLA) Scientific Sessions, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, chief of the section of cardiovascular research and professor of medicine at Baylor College of Medicine, discussed the history of LDL control as a quality and performance measure according to CMS, the impact of its removal in more
EULAR: MRI, PET can be used ‘as an alternative’ to ultrasound for cranial arteries in GCA
June 07 ,2023
Overview:MRI and PET scans are viable alternatives to ultrasound for cranial arteries in patients with suspected giant cell arteritis, according to a 2023 update of EULAR’s recommendations for imaging in large vessel vasculitis.“We wanted to develop recommendations for the use of imaging in several aspects of large vessel vasculitis diagnosis, monitoring and outcome prediction,” Christian Dejaco, MD, PhD, a member of the EULAR standing committee on musculoskeletal imaging, told attendees.Dejaco, who is also a consultant and associate professor in the department of rheumatology at the more
Better cardiovascular scores linked to better cognition
June 06 ,2023
Overview:INDIANAPOLIS — Measures of cardiovascular health, which include sleep, were found to be associated with cognitive performance in middle-aged and older adults, according to research presented at SLEEP 2023.Sleep was recently added to the American Heart Association’s Life’s Simple 7, making it Life’s Essential 8 (LE8), Yuqi Shen, a graduate student in biobehavioral health in Penn State University’s College of Health and Human Development, said in her presentation.The “key measures for improving and maintaining cardiovascular health,” as the AHA says on more
Coronary CT may be best diagnostic strategy when evaluating stable chest pain
June 06 ,2023
Overview:For adults with stable chest pain, coronary CTA may be as useful as direct invasive coronary angiography and may be the best diagnostic strategy vs. stress testing and single-photon emission CT myocardial perfusion imaging, data show.“The diagnostic assessment of stable chest pain is a public health and economic challenge,” Francesco Burzotta, MD, PhD, director of the valve heart diseases clinical pathway, head of the stable heart diseases unit and senior interventional cardiologist at Gemelli University Hospital in Rome and assistant professor at the Institute of Cardiology at more
Andexanet alfa postmarketing trial stopped early due to superior efficacy
June 06 ,2023
Overview:AstraZeneca announced the ANNEXA phase IV trial assessing the safety and efficacy of andexanet alfa stopped early after achieving prespecified criteria on hemostatic efficacy vs. usual care, according to a press release.Andexanet alfa (Andexxa) is approved for patients prescribed oral factor Xa inhibitor treatment, including apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) and rivaroxaban (Xarelto, Janssen/Bayer), who are experiencing an intracranial hemorrhage. The decision was based on achieving prespecified stopping criteria of superior hemostatic efficacy, the ability to limit the more
AAA stent graft tied to durable performance, low 10-year rates of aneurysm-related death
June 06 ,2023
Overview:A stent graft for abdominal aortic aneurysm repair was associated with durable performance and low rates of aneurysm-related mortality at 10 years, researchers reported at the Charing Cross Symposium.As Healio previously reported, the ENGAGE registry was a real-world study of more than 1,200 patients who underwent endovascular aneurysm repair with the stent graft (Endurant, Medtronic). Final 10-year results of the extended follow-up cohort of 390 patients were presented at Charing Cross by Hence J.M. Verhagen, MD, PhD, professor and chief of vascular surgery at Erasmus University Medical more
Same-day discharge protocol identifies patients who respond well to AF ablation
June 06 ,2023
Overview:Use of a standardized protocol identified candidates for same-day discharge after catheter ablation for atrial fibrillation and also predicted procedural outcomes, researchers reported at Heart Rhythm 2023.The researchers conducted an analysis of 2,332 patients from the REAL-AF registry of people with paroxysmal or persistent AF who underwent radiofrequency catheter ablation (Thermocool SmartTouch or Thermocool SmartTouch SF, Biosense Webster).“In 2021, the REAL-AF team developed a same-day discharge protocol, and we implemented this protocol in a matched-cohort single-center study,” more
Combination therapy in patients with new pulmonary arterial hypertension often delayed
June 06 ,2023
Overview:WASHINGTON — Only 8% of patients with pulmonary arterial hypertension initiating combination therapy were given both medications on the same day, according to research presented at the American Thoracic Society International Conference.“Since a vast majority of patients are still not escalated to dual combination therapy, we expect these findings will spur clinicians to assess their PAH patient’s risk status early and often and consider the latest 2022 ESC/ERS Guidelines to initiate or rapidly escalate to dual combination therapy with a phosphodiesterase-5 inhibitor (PDE5i) more
Team-based intervention reduces risk for hypertension complications
June 05 ,2023
Overview:A team-based, multicomponent program was linked to risk reductions for several CVD and health outcomes in patients with hypertension when compared with usual care, according to researchers.“Team-based care, standardized management protocols, clinician training, and patient empowerment have shown effectiveness for BP reduction, whereas multilevel, multicomponent interventions have been most effective for lowering systolic BP,” Esther Y. T. Yu, MBBS, a clinical assistant professor in the department of family medicine and primary care at the University of Hong Kong, and colleagues more
Optimal Antiplatelet Therapy In NSTE-ACS: Results From A Novel Crowdsourcing Survey
July 07 ,2021
Overview:The choice and duration of antiplatelet therapy in NSTE-ACS undergoing PCI is complex and is a hotly debated topic – particularly amongst patients at high bleeding risk. To gain insight […] more
Results of an international crowdsourcing survey on the utilisation of antiplatelet therapy in NSTE-ACS
June 09 ,2021
Overview:Choosing an antiplatelet strategy in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) at high bleeding risk (HBR), undergoing percutaneous coronary intervention (PCI), is complex given that one must […] more
Hello world!
February 04 ,2021
Overview:Welcome to WordPress. This is your first post. Edit or delete it, then start writing! The post Hello world! appeared first on World Heart Federation. more
ACC.20/WCC Virtual continues!
April 05 ,2020
Overview:The World Heart Federation and American College of Cardiology held their first ever virtual congress March 28-30. But it’s not over. All of the ACC.20/WCC Virtual live sessions are now available […] more
2020 ISCP Annual Meeting cancelled
February 26 ,2020
Overview:Notice of Cancellation We regret to have to inform our colleagues and friends that the 2020 ISCP Annual Scientific Meeting in Miami will now be cancelled. The Board of Directors […] more
European Cardiology Review (ECR) now on PubMed and PubMed Central
October 30 ,2018
Overview: European Cardiology Review (ECR) confirms that it has been accepted for indexing on PubMed Central and PubMed. All ECR articles starting from the first issue in July 2014, […] more
WHF to attend the WHO Executive Board meeting in January 2017
January 23 ,2017
Overview:From 23 January to 01 February 2017, the World Health Organization(WHO) will host the 140th session. From 23 January to 01 February 2017, the World Health Organization(WHO) will host the […] more